Skip to main content
ANL logo

Adlai Nortye Ltd. (ANL) Stock: Price, Forecast & Analyst Target

Adlai Nortye Ltd. (ANL) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $9.06 (+3.66%), as of the Nov 19, 2026 trading session; market cap $583M.

Educational signal · not a buy or sell recommendation · How to read this

$9.06 +$0.32 (+3.66%) Market Cap $583M

Adlai Nortye Ltd. · ANL · NASDAQ

Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on developing innovative pharmaceutical products.

Price as of Nov 19, 2026

Key Statistics

29 of 100

MoonshotScore v2 · Adlai Nortye (ANL)

Weak
Business Quality Thin (26)
Financial Safety Strained (35)
Valuation Fair (64)
Growth Durability Growing (62)
Momentum Surging (80)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Strong price action running well ahead of the business — weak quality underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Fair; Growth Durability: Growing; Momentum: Surging.

  • quarterly revenue $7M (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 5 of the last 8 reports
  • Altman Z 7.36 · Piotroski F 3

Holding back: weak fundamentals

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ANL (57 recorded, newest six shown)
RecordedScoreBand
31Weak
28Weak
29Weak
29Weak
29Weak
29Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$9.06
Change on the day+3.66%
52-week range$0.8786 – $17.25
Market capitalisation$583M—
Price / earnings (trailing)-30.84
Shares traded on the day216.1K

Price & events

Other perspectives

Council score for Adlai Nortye (ANL): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Weak
Financial Safety Weak
Valuation Moderate
Growth Durability Moderate
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Moderate
ROE Negative
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Adlai Nortye (ANL), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Adlai Nortye Ltd. (ANL) is listed on NASDAQ. It employs 109 people and is led by Yang Lu. In Q2 FY2026 it reported revenue of $7M and net income of -$3M. The market values it at $583M.

2 · Latest results

What do the latest results show for Adlai Nortye (ANL)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $7M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$7M-$3M-$0.17 (diluted)
Q1 FY2026$7M-$3M-$0.17 (diluted)
Q4 FY2025$3M-$9M-$0.81 (diluted)
Q3 FY2025$3M-$9M-$0.81 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Adlai Nortye (ANL)?

Short answer

The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is weak fundamentals. The distress and quality screens read Altman Z 7.36 · Piotroski F 3. Trailing ratios: ROE -20.2% · ROA -8.7% · current ratio 9.55.

Data-derived red flags

  • Negative return on equity (-20.2%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Adlai Nortye (ANL)?

Short answer · as of

Current published price targets run low $31.00 · high $49.00 · consensus $37.33 · median $32.00 against a quoted price of $9.06 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Adlai Nortye compare with its peers?

Short answer

Adlai Nortye's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.34 Nov 19, 2026$119B85 5-pillar Nov 18, 2026
AstraZeneca PLC (AZN) Named competitor$178.76 Nov 18, 2026$277B85 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Named competitor$137.78 Nov 18, 2026$340B69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
LB Pharmaceuticals Inc (LBRX) Same industry, near in market value$40.04 Nov 19, 2026$1.30B69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
Vor Biopharma, Inc. (VOR) Same industry, near in market value$18.52 Nov 19, 2026$1.14B66 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Adlai Nortye (ANL) — this page$9.06$583M29

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$31.00 – $49.00
Consensus target
$37.33
Median target
$32.00

Consensus record · Captured .

Measured against a quoted price of $9.06 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ANL in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ANL in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Adlai Nortye (ANL)?

Read these with our analysis →

What Investors Ask About Adlai Nortye (ANL)

These answers are editorial: 1 of these 9 answers is drawn from the ANL research dossier (written May 8, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ANL?

ANL carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is ANL a good stock to buy?

Stock Expert AI does not rate ANL buy, sell or hold. Adlai Nortye Ltd. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ANL stock price today?

The last price recorded for Adlai Nortye Ltd. (ANL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ANL price target?

The analyst consensus price target for Adlai Nortye Ltd. (ANL), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for ANL?

The primary risks for Adlai Nortye include the potential failure of clinical trials, regulatory hurdles, and competition from established pharmaceutical companies. Regulatory delays or rejection of drug approvals could also hinder the company's progress.

What are the key factors to evaluate for ANL?

Adlai Nortye Ltd. (ANL) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. These partnerships could enhance the company's financial stability and market reach. Not financial advice.

How frequently does ANL data refresh on this page?

ANL's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ANL's recent stock price performance?

Adlai Nortye Ltd. (ANL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising lead product in Phase III clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ANL overvalued or undervalued right now?

Adlai Nortye Ltd. (ANL) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 8, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 12 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.